ATNX — Athenex Share Price
Last trade - 00:00- $115.88m
- $161.96m
- $144.39m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.76 | ||
| Price to Tang. Book | 11.17 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.99 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -45.05% | ||
| Return on Equity | -76.73% | ||
| Operating Margin | -120.21% | ||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 20.55 | 38.04 | 89.1 | 101.23 | 144.39 | 126.55 | 121.75 | 59.6% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Athenex, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The Oncology Innovation Platform is engaged in research and development of its drugs. The Global Supply Chain Platform is engaged in supplying active pharmaceutical ingredient (APIs) to clinical and commercial efforts. The Commercial Platform is focused on the sales and marketing of its drugs. Its product pipeline includes Orascovery, Src Kinase Inhibition, Cell Therapy and Arginine Deprivation Therapy. Its lead product candidate Orascovery platform technology is based on the novel oral P-gp pump inhibitor molecule, encequidar. Its Src Kinase inhibition platform technology is based on novel small molecule compounds including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization.
Directors
- Johnson Lau CHM (47)
- Steven Adams CFO (53)
- William Zuo CEX (59)
- Jeffrey Yordon COO (72)
- Teresa Bair SVP (50)
- Timothy Cook OTH (59)
- Rudolf Kwan OTH (68)
- A. Kim Campbell LED (74)
- Manson Fok DRC (64)
- Stephanie Davis IND (57)
- Jordan Kanfer IND (51)
- Robert Spiegel IND (71)
- Kwan Hung Tsang IND (56)
- John Vierling IND (74)
- Jinn Wu IND (72)
- Last Annual
- December 31st, 2020
- Last Interim
- September 30th, 2021
- Incorporated
- November 4th, 2003
- Public Since
- June 14th, 2017
- No. of Shareholders
- 97
- No. of Employees
- 593
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 109,319,039
- Address
- 1001 Main St Ste 600, BUFFALO, 14203-1009
- Web
- https://www.athenex.com/
- Phone
- +1 7168988625
- Contact
- Tim McCarthy
- Auditors
- Deloitte & Touche LLP
Latest News for ATNX
Upcoming Events for ATNX
Q4 2021 Athenex Inc Earnings Release
Q1 2022 Athenex Inc Earnings Release
Athenex Inc Annual Shareholders Meeting
Similar to ATNX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
ACADIA Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 12:08 UTC, shares in Athenex are trading at $1.06. This share price information is delayed by 15 minutes.
Shares in Athenex last closed at $1.06 and the price had moved by -90.46% over the past 365 days. In terms of relative price strength the Athenex share price has underperformed the S&P500 Index by -92.23% over the past year.
The overall consensus recommendation for Athenex is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Athenex does not currently pay a dividend.
Athenex does not currently pay a dividend.
Athenex does not currently pay a dividend.
To buy shares in Athenex you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.06, shares in Athenex had a market capitalisation of $115.88m.
Here are the trading details for Athenex:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ATNX
Based on an overall assessment of its quality, value and momentum Athenex is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Athenex is $7.50. That is 607.55% above the last closing price of $1.06.
Analysts covering Athenex currently have a consensus Earnings Per Share (EPS) forecast of -$1.12 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Athenex. Over the past six months, its share price has underperformed the S&P500 Index by -74.8%.
As of the last closing price of $1.06, shares in Athenex were trading -67.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Athenex PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.06.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Athenex's management team is headed by:
- Johnson Lau - CHM
- Steven Adams - CFO
- William Zuo - CEX
- Jeffrey Yordon - COO
- Teresa Bair - SVP
- Timothy Cook - OTH
- Rudolf Kwan - OTH
- A. Kim Campbell - LED
- Manson Fok - DRC
- Stephanie Davis - IND
- Jordan Kanfer - IND
- Robert Spiegel - IND
- Kwan Hung Tsang - IND
- John Vierling - IND
- Jinn Wu - IND